These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
6. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534 [TBL] [Abstract][Full Text] [Related]
7. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. Kuwashima N; Nishimura F; Eguchi J; Sato H; Hatano M; Tsugawa T; Sakaida T; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Gambotto A; Pollack IF; Storkus WJ; Okada H J Immunol; 2005 Aug; 175(4):2730-40. PubMed ID: 16081851 [TBL] [Abstract][Full Text] [Related]
8. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene. Cao X; Wang Q; Ju DW; Tao Q; Wang J J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706 [TBL] [Abstract][Full Text] [Related]
9. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225 [TBL] [Abstract][Full Text] [Related]
10. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956 [TBL] [Abstract][Full Text] [Related]
11. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052 [TBL] [Abstract][Full Text] [Related]
12. Cytokine immuno-gene therapy for treatment of brain tumors. Lichtor T; Glick RP J Neurooncol; 2003 Dec; 65(3):247-59. PubMed ID: 14682375 [TBL] [Abstract][Full Text] [Related]
13. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307 [TBL] [Abstract][Full Text] [Related]
14. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Björkdahl O; Dohlsten M; Sjögren HO Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695 [TBL] [Abstract][Full Text] [Related]
15. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596 [TBL] [Abstract][Full Text] [Related]
16. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752 [TBL] [Abstract][Full Text] [Related]
17. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. Salem ML; Kadima AN; Zhou Y; Nguyen CL; Rubinstein MP; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE J Immunol; 2004 May; 172(9):5159-67. PubMed ID: 15100252 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. Winter H; Hu HM; McClain K; Urba WJ; Fox BA J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488 [TBL] [Abstract][Full Text] [Related]
19. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. Prins RM; Vo DD; Khan-Farooqi H; Yang MY; Soto H; Economou JS; Liau LM; Ribas A J Immunol; 2006 Dec; 177(12):8448-55. PubMed ID: 17142742 [TBL] [Abstract][Full Text] [Related]
20. The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. Park SH; Kyin T; Bendelac A; Carnaud C J Immunol; 2003 Feb; 170(3):1197-201. PubMed ID: 12538676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]